OpGen

OpGen Receivables

The Accounts Receivable of OpGen (OPGN) as of Oct 28, 2026 is 29,300.00 USD. In the previous year, Accounts Receivable was 103,300.00 USD — a change of -71.64% (lower).

Receivables

29,300.00USD

YoY

-71.64%

Last updated:

Accounts Receivable of OpGen is 2024 29,300.00 USD. Accounts Receivable of OpGen was 2023 103,300.00 USD. It decreases by -71.64% lower compared to the previous year.

The OpGen Receivables history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Receivables
Date
Receivables
Jan 1, 2017
810,000.00 USD
Jan 1, 2018
374,000.00 USD
Jan 1, 2019
568,000.00 USD
Jan 1, 2020
653,000.00 USD
Jan 1, 2021
1.17 M USD
Jan 1, 2022
514,000.00 USD
Jan 1, 2023
103,300.00 USD
Jan 1, 2024
29,300.00 USD
The OpGen Receivables history
YEARReceivablesYoY
29,300.00USD-71.64%
103,300.00USD-79.90%
514,000.00USD-56.14%
1.17 MUSD+79.48%
653,000.00USD+14.96%
568,000.00USD+51.87%
374,000.00USD-53.83%
810,000.00USD+49.45%
542,000.00USD-20.18%
679,000.00USD+34.72%
504,000.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

OpGen Stock analysis

What does OpGen do? OpGen, Inc. generates revenue through its Acuitas-branded high-resolution DNA tests and bioinformatics solutions, targeting healthcare providers and hospitals globally. The company's molecular diagnostics and informatics products help combat infectious diseases by providing precise diagnostic information on life-threatening infections and multidrug-resistant microorganisms. These solutions guide clinicians in managing patient outcomes and hospital biome protection through customized screening and surveillance. The firm's DNA tests and bioinformatics address antibiotic resistance, offering data-driven insights for healthcare decision-making. The company's Acuitas trade name is used for its high-resolution DNA tests, which are marketed to healthcare settings focused on infectious disease management. OpGen's products help hospitals manage patient care decisions and protect against the spread of infections caused by multidrug-resistant pathogens. The firm's global network of customers and partners includes healthcare providers seeking to implement pathogen surveillance systems for improved infection control. OpGen's business model centers on delivering molecular information solutions that combine DNA testing with bioinformatics, creating a comprehensive approach to infectious disease management. The company's focus on antibiotic resistance and multidrug-resistant microorganisms drives demand for its Acuitas products, which are positioned as tools for guiding clinical decisions and optimizing hospital infection control protocols. OpGen is one of the most popular companies on Eulerpool.

Frequently Asked Questions about OpGen stock

Accounts Receivable of OpGen is 29,300.00 USD in 2024.

Accounts Receivable of OpGen changed from 103,300.00 USD to 29,300.00 USD, representing a -71.64% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Accounts Receivable OpGen since 2006 – with annual values, charts, and detailed analysis.

Receivables represent money owed to the company by customers for goods or services delivered. High receivables relative to revenue may indicate collection issues.

Accounts Receivable's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Accounts Receivable's OpGen historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — OpGen

All Key Metrics — OpGen